CYCLOPHARM LIMITED (CYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CYC - CYCLOPHARM LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.53
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.375

20 Nov
2024

0.000

OPEN

$1.38

0.000

HIGH

$1.40

17,742

LOW

$1.38

TARGET
$2.70 96.4% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CYC: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 5.1 - 10.6 xxx
DPS (cps) xxx 0.5 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.26%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.36

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 01/09 - ex-div 0.5c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-5.1
DPS All xxxxxxxxxxxxxxx0.5
Sales/Revenue xxxxxxxxxxxxxxx27.1 M
Book Value Per Share xxxxxxxxxxxxxxx34.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-7.2 M
Net Profit Margin xxxxxxxxxxxxxxx-17.32 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-13.67 %
Return on Invested Capital xxxxxxxxxxxxxxx-12.22 %
Return on Assets xxxxxxxxxxxxxxx-9.85 %
Return on Equity xxxxxxxxxxxxxxx-13.67 %
Return on Total Capital xxxxxxxxxxxxxxx-22.97 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-8.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx4 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx12 M
Price To Book Value xxxxxxxxxxxxxxx5.62

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx1.98 %
Cost of Goods Sold xxxxxxxxxxxxxxx23 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx4 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

28/08/2024

1

Buy

$2.70

96.36%

Cyclopharm reported a -19% decline in 1H24 revenue, due to the exclusion of a FY23 one-off item on capital equipment which was not repeated, Bell Potter notes.

Expenses advanced 10% on the previous corresponding period, including a higher rate on commercialisation versus R&D.

The analyst observes a slower than expected rollout of Technegas system in the US, although US hospitals are benefitting from an increased reimbursement base of some estimated US$828 per patient.

Bell Potter lowers FY24 EPS forecast by -42% with expectations Cyclopharm will be profitable in FY26.

Buy rating unchanged. Target price falls to $2.70 from $3.10.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -10.60 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.60 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

CYC STOCK CHART

FNArena News on CYC

1
Rudi’s View: The Importance Of ‘Quality’ Growth

Nov 21 2024 - Rudi's View
2
Rudi’s View: A Rally With No Earnings Support

Nov 14 2024 - Rudi's View
3
Rudi’s View: Trump Returns, What Now?

Nov 07 2024 - Rudi's View
4
Rudi’s View: US Earnings & The Election

Oct 31 2024 - Rudi's View
5
Rudi’s View: Earnings, Best Ideas & Favourite Stock Picks

Oct 24 2024 - Rudi's View

Latest Medical Equipment & Devices News

1
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
2
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
3
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
4
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
5
ResMed Silences The Doubters

Apr 29 2024 - Australia
6
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
7
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
8
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
9
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
10
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps